Developing personalised vaccines to prevent childhood leukaemia relapse
Childhood leukaemia can return after initially successful treatment, leaving children with limited treatment options. Residual cancer cells can escape an immune system weakened by prior therapies. Preventing recurrence remains an unmet need in paediatric cancer care.
Spes Immunotherapeutics is developing personalised vaccines to prevent childhood leukaemia relapse. The approach targets cancer-specific fusion proteins to help the immune system recognise and eliminate residual leukaemia cells after treatment.
What stands out about Spes Immunotherapeutics
Reports winning the i4KIDS Innovation Day Award 2025, awarded by Fundació Hospital Sant Joan de Déu.
AEI lists a €115,500 Torres Quevedo grant for Spes’s acute-leukaemia relapse-prevention vaccine project, reference PTQ2025-014533.
Selected for the 2025 i4KIDS Acceleration Programme with its personalised childhood leukaemia relapse-prevention vaccine project.
Co-founder Ricky Tirtakusuma has postdoctoral experience at St. Jude and VHIO, with research spanning leukaemia and cancer immunology.
Spes reports a strategic agreement with BCN Peptides to supply therapeutic-grade peptides from preclinical batches through clinical trials.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.